Table 4.
Summary of laboratory data
| Dotinurad (n = 102) | Benzbromarone (n = 99) | |||||
|---|---|---|---|---|---|---|
| Standard range | Visit | Mean ± SD | 95% CI | Mean ± SD | 95% CI | |
| AST (U/L) | 10–40 | Run-in period | 25.1 ± 7.3 | 23.7–26.6 | 24.6 ± 8.2 | 22.9–26.2 |
| Final visit | 25.6 ± 9.4 | 23.7–27.4 | 24.4 ± 9.1 | 22.6–26.2 | ||
| ALT (U/L) | 5–45 | Run-in period | 26.5 ± 11.4 | 24.3–28.7 | 26.3 ± 14.5 | 23.4–29.2 |
| Final visit | 27.3 ± 15.1 | 24.3–30.2 | 25.1 ± 15.0 | 22.1–28.1 | ||
| γ-GTP (U/L) | < 79 | Run-in period | 52.4 ± 36.2 | 45.3–59.5 | 59.3 ± 45.7 | 50.2–68.5 |
| Final visit | 52.6 ± 38.2 | 45.1–60.1 | 52.4 ± 42.9 | 43.8–60.9 | ||
| Serum creatinine (mg/dL) | 0.65–1.09 | Run-in period | 0.963 ± 0.147 | 0.934–0.992 | 0.961 ± 0.164 | 0.928–0.994 |
| Final visit | 0.953 ± 0.167 | 0.920–0.986 | 0.956 ± 0.183 | 0.920–0.993 | ||
| eGFRa | – | Run-in period | 65.3 ± 11.5 | 63.07–67.61 | 66.2 ± 12.0 | 63.76–68.57 |
| (mL/min/1.73 m2) | Final visit | 66.4 ± 12.8 | 63.97–69.00 | 66.8 ± 13.0 | 64.25–69.47 | |
aeGFR at the final visit was calculated by Post hoc analysis
95% CI: 95% confidence interval